OZEMPIC (SEMAGLUTIDE)
Ozempic: FDA Approval, Uses, and Prescriptions
Ozempic (semaglutide) is a GLP-1 receptor agonist manufactured by Novo Nordisk and FDA-approved for type 2 diabetes management and cardiovascular risk reduction — not for weight loss. This guide explains what Ozempic is, how it differs from Wegovy, its off-label use in weight management, cost, and how to get a prescription legally.
Important: Ozempic is FDA-approved for type 2 diabetes and cardiovascular risk reduction — not for chronic weight management. Wegovy (same active ingredient, higher dose) is the FDA-approved option for weight management. A licensed clinician may prescribe Ozempic off-label for weight management; this is their clinical decision. This site does not advise on prescribing decisions.
What Is Ozempic?
Ozempic is a brand-name prescription medication manufactured by Novo Nordisk. Its active ingredient is semaglutide — a GLP-1 receptor agonist that mimics the action of glucagon-like peptide-1, a gut hormone that regulates blood sugar, appetite, and digestion.
Ozempic is available in weekly subcutaneous injection form in doses of 0.25 mg (starter dose), 0.5 mg, 1.0 mg, and 2.0 mg. It was initially FDA-approved in 2017 for the treatment of type 2 diabetes in adults, and subsequently received expanded approval for reducing the risk of major adverse cardiovascular events (heart attack, stroke, death) in adults with type 2 diabetes and established cardiovascular disease.
Although Ozempic contains the same active ingredient as Wegovy (semaglutide), it is a different FDA-approved product with a different indication and different approved dose range. The FDA-approved weight management product is Wegovy (semaglutide 2.4 mg) — not Ozempic.
FDA-Approved Uses for Ozempic
Ozempic is FDA-approved for two indications:
- Type 2 diabetes management: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Cardiovascular risk reduction: To reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and established cardiovascular disease.
Ozempic is not FDA-approved for chronic weight management. Using it for weight loss without a type 2 diabetes diagnosis constitutes off-label use. Off-label prescribing is legal and common in medicine, but it is a clinical decision made by a licensed prescriber — not a recommendation this site makes.
How Ozempic Works
Ozempic works by activating GLP-1 receptors, which produces several effects relevant to both diabetes management and weight:
- Stimulates insulin secretion in a glucose-dependent manner (only when blood sugar is elevated), reducing hyperglycemia risk
- Suppresses glucagon secretion after meals, reducing the liver's glucose output
- Slows gastric emptying, reducing post-meal blood sugar spikes
- Acts on brain appetite centers to reduce hunger and increase satiety
These effects together help control blood sugar in type 2 diabetes and are also associated with weight reduction — which is why Ozempic is often discussed in the context of weight management, even though it is not FDA-approved for that use.
Ozempic vs. Wegovy: Important Differences
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide |
| Max Dose | 2.0 mg weekly | 2.4 mg weekly |
| FDA Approval | Type 2 diabetes + CV risk reduction | Chronic weight management |
| Insurance Coverage | More commonly covered (diabetes) | Less consistent (weight management) |
| FDA Approval Year | 2017 | 2021 |
Off-Label Use for Weight Management
Ozempic has been widely discussed and used for weight management, even though this is not its FDA-approved indication. This is because the active ingredient (semaglutide) is the same as in Wegovy, and the weight-loss effects observed in clinical trials are real — they are part of the mechanism of action.
Licensed clinicians may prescribe Ozempic off-label for weight management in patients who meet certain criteria. This is a clinical decision based on the patient's medical history, insurance situation, clinical indication, and the prescriber's judgment. This site does not advise on when off-label prescribing is appropriate — that is a decision for a licensed clinician.
Patients with type 2 diabetes seeking GLP-1 treatment for both glycemic control and weight management may find Ozempic directly on-label for their situation. Those without diabetes seeking GLP-1 treatment for weight management are better candidates for Wegovy, which is on-label for that purpose.
Ozempic Cost and Insurance Coverage
Ozempic's approximate list price is $800–$1,000 per month without insurance, depending on dose. Insurance coverage is generally more accessible for Ozempic than for Wegovy because diabetes medications are more commonly covered than weight-management medications. Prior authorization is frequently required.
Novo Nordisk offers savings programs for Ozempic for eligible commercially insured patients — terms and eligibility requirements apply and change over time. See our Ozempic cost guide and full GLP-1 cost guide for details. Always verify current pricing with the manufacturer or your pharmacy.
Frequently Asked Questions About Ozempic
Ozempic is FDA-approved for type 2 diabetes management and cardiovascular risk reduction — not for weight loss. The FDA-approved weight loss product containing semaglutide is Wegovy (at a higher 2.4 mg dose). Clinicians may prescribe Ozempic off-label for weight management in some patients; this is their clinical decision, not a recommendation this site makes. If you are seeking GLP-1 treatment specifically for weight management and do not have type 2 diabetes, ask your clinician about Wegovy.
Yes. Ozempic is a prescription-only drug under US federal law. It cannot be legally obtained without a valid prescription from a licensed clinician. Any source offering Ozempic without a prescription is operating outside the law. See our GLP-1 without a prescription guide.
Ozempic is more commonly covered by insurance than weight-management GLP-1 medications because it is approved for type 2 diabetes — an indication that most commercial insurance plans cover with prior authorization. Coverage depends on your specific plan, the prescribed indication, and formulary placement. If prescribed off-label for weight management, insurance may not cover it even if it would for diabetes. Check your plan's formulary and see our insurance coverage guide.
Ozempic's approximate list price is $800–$1,000 per month without insurance or savings programs. With insurance coverage (common for the diabetes indication with prior authorization), out-of-pocket costs can be much lower. Novo Nordisk offers savings programs for eligible commercially insured patients. See our Ozempic cost guide for details. Always verify current pricing with your pharmacy or the manufacturer.
GET A PRESCRIPTION THROUGH LICENSED TELEHEALTH
Access Ozempic Through a Licensed Provider
Ozempic requires a prescription. Compare telehealth providers that offer Ozempic and other GLP-1 medications with real clinician evaluations — no guaranteed approvals.
We may earn a referral fee if you complete a consultation through a partner link. This is not medical advice. Talk with a licensed clinician.